Swedish Orphan Biovitrum AB: Sobi to streamline nirsevimab c

Nirsevimab economics simplified through a new royalty agreement with Sanofi and the termination of the participation agreement with AstraZeneca Alignment will provide Sobi benefit through

Related Keywords

Stockholm , Sweden , Australia , United States , America , Thomas Kudsk Larsen , Prnewswire Sobi , Youtube , Astrazeneca , Sobi Investor Relations Team , Linkedin , North America , Middle East , Sobi Media , Swedish , Orphan , Iovitrum , Gobi , Treamline , Nirsevimab , Contractual , Arrangements ,